Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Bimzelx | bimekizumab | Ankylosing spondylitis | Active | |||
Lumakras | sotorasib | KRAS G12C-mutated advanced NSCLC | Do not reimburse | Active | ||
Ultomiris | ravulizumab | Neuromyelitis optica spectrum disorder (NMOSD) | Reimburse with clinical criteria and/or conditions | Active | ||
Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Reimburse with clinical criteria and/or conditions | Active | ||
Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Reimburse with clinical criteria and/or conditions | Active | ||
N/A | rivaroxaban | Venous thromboembolic events (VTE) | Reimburse with clinical criteria and/or conditions | Active | ||
Epidiolex | cannabidiol | Dravet Syndrome (DS) | Reimburse with clinical criteria and/or conditions | Active | ||
N/A | eltrombopag | Severe Aplastic Anemia (SAA) | Reimburse with clinical criteria and/or conditions | Active | ||
Hemgenix | etranacogene dezaparvovec | Hemophilia B | Reimburse with clinical criteria and/or conditions | Active | ||
Awiqli | insulin icodec | Diabetes mellitus, type 2 | Active |